Barclays Sticks to Its Buy Rating for Arcellx Inc (ACLX)
Barclays analyst Peter Lawson maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $115.00. The ...
Arcellx reports FY24 EPS ($2.00), consensus ($1.50)
Reports FY24 revenue $107.9M, consensus $121.7M. “2024 was a transformational year for Arcellx (ACLX) as our ASH data presentations for ...
Business Wire17 天
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer ...